Structure and property based design of pyrazolo[1,5-a]pyrimidine inhibitors of CK2 kinase with activity in vivo

ACS Medicinal Chemistry Letters

Volumn 4, Issue 8, 2013, Pages 800-805

  Dowling, James E ^a   Alimzhanov, Marat ^a   Bao, Larry ^a   Block, Michael H ^a   Chuaqui, Claudio ^a   Cooke, Emma L ^a   Denz, Christopher R ^a   Hird, Alex ^a   Huang, Shan ^a   Larsen, Nicholas A ^a   Peng, Bo ^a   Pontz, Timothy W ^a   Rivard Costa, Caroline ^a   Saeh, Jamal Carlos ^a   Thakur, Kumar ^a   Ye, Qing ^a   Zhang, Tao ^a   Lyne, Paul D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CK2 kinase; matched molecular pair; oxetane; pyrazolo 1,5 a pyrimidine

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; PLASMA PROTEIN; POTASSIUM CHANNEL HERG; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; HINGE REGION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LIPOPHILICITY; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

MURINAE;

EID: 84881422967     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400197u     Document Type: Article

References (17)

1. Ruzzene, M.; Pinna, L. A. Addiction to protein kinase CK2: A common denominator of diverse cancer cells? Biochim. Biophys. Acta 2010, 1804, 499-504
2. Di Maira, G.; Brustolon, F.; Pinna, L. A.; Ruzzene, M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells Cell. Mol. Life Sci. 2009, 66, 3363-3373
3. Dominguez, I.; Sonenshein, G. E.; Seldin, D. C. CK2 and its role in Wnt and NF-kappa B signaling: Linking development and cancer Cell. Mol. Life. Sci. 2009, 66, 1850-1857
4. Laramas, M.; Pasquier, D.; Filhol, O.; Ringeisen, F.; Descotes, J.-L.; Cochet, C. Eur. J. Cancer 2007, 43, 928-934
5. Ji, H.; Wang, J.; Nika, Trembley, J. H.; Unger, G. M.; Tobolt, D. K.; Korman, V. L.; Wang, G.; Ahmad, K. A.; Slaton, J. W.; Kren, B. T.; Ahmed, K. Systemic administration of antisense oligonucleotides simultaneously targeting CK2alpha and alpha' subunits reduces orthotopic xenograft prostate tumors in mice Mol. Cell. Biochem. 2011, 356, 21-35
6. Sarno, S.; Papinutto, E.; Franchin, C.; Bain, J.; Elliott, M.; Meggio, F.; Kazimierczuk, Z.; Orzeszko, A.; Zanotti, G.; Battistutta, R.; Pinna, L. A. ATP site-directed inhibitors of protein kinase CK2: an update Curr. Top. Med. Chem. 2011, 11, 1340-1351
7. Pierre, F.; Chua, P. C.; O'Brien, S. E.; Siddiqui-Jain, A.; Bourbon, P.; Haddach, M.; Michaux, J.; Nagasawa, J.; Schwaebe, M. K.; Stefan, E.; Vialettes, A.; Whitten, J. P.; Chen, T. K.; Darjania, L.; Stansfield, R.; Anderes, K.; Bliesath, J.; Drygin, D.; Ho, C.; Omori, M.; Proffitt, C.; Streiner, N.; Trent, K.; Rice, W. G.; Ryckman, D. M. Discovery and SAR of 5-(3-chlorophenylamino) benzo[c] [2,6] naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer J. Med. Chem. 2011, 54, 635-54
8. Dowling, J. E.; Bao, L.; Brassil, P.; Chen, H.; Chuaqui, C.; Cooke, E. L.; Denz, C. R.; Larsen, N. A.; Lyne, P. D.; Peng, B.; Pontz, T. W.; Racicot, V.; Russell, D.; Su, N.; Thakur, K.; Wu, A.; Ye, Q.; Zhang, T. Potent and selective inhibitors of CK2 kinase identified through structure-guided hybridization ACS Med. Chem. Lett. 2012, 3, 278-283
9. Di Maira, G.; Brustolon, F.; Pinna, L. A.; Ruzzene, M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells Cell. Mol. Life Sci. 2009, 66, 3363-3373
10. Kranenburg, M.; van der Burgt, Y. E. M.; Kamer, P. C. J.; van Leeuwen, P. W. N. M.; Goubitz, K.; Fraanje, J. New diphosphine ligands based on heterocyclic aromatics inducing very high regioselectivity in rhodium-catalyzed hydroformylation: effect of the bite angle Organometallics 1995, 14, 3081-3089
11. Nie, Z.; Perretta, C.; Erickson, P.; Margosiak, S.; Almassy, R.; Lu, J.; Averill, A.; Yager, K. M.; Chu, S. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2 Bioorg. Med. Chem. Lett. 2007, 17, 4191-4195
12. Figure produced using Pymol. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002; see http://www.pymol.org.
13. Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. Oxetanes in drug discovery: Structural and synthetic insights J. Med. Chem. 2010, 53 (8) 3227-3246
14. Burkhard, J. A.; Wuitschik, G.; Rogers-Evans, M.; Müller, K.; Carreira, E. M. Oxetanes as versatile elements in drug discovery and synthesis Angew. Chem., Int. Ed. 2010, 49 (48) 9052-9067
15. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
16. Image generated using TREEspot Software Tool and reprinted with permission from KINOMEscan, a division of DiscoveRx Corporation, © DISCOVERX CORPORATION 2010.
17. Dowling, J. E.; Alimzhanov, M.; Bao, L.; Chuaqui, C.; Denz, C.; Ferguson, A.; Graff, C.; Liu, Z.-Y.; Lyne, P.; Racicot, V.; Wu, A.; Wu, J.; Ye, Q.; Cooke, E. L. Discovery and characterization of AZ968, a potent and selective inhibitor of CK2 kinase with effects on AKT signaling in vivo. Poster presented at the 103rd Annual Meeting of the American Association for Cancer Research, March 31-April 4, 2012. Chicago, IL; Abstract No. 3907.